American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common ...

The EMA, as well as the FDA in the US, have approved labelling for Wegovy that mentions that semaglutide has been ... people with a family history of thyroid cancer. In a statement, the EMA ...

Typically, semaglutide is subcutaneously administered ... gallbladder disease, medullary thyroid cancer, or type 2 multiple endocrine neoplasia were excluded from the study. Participants ...

Animal studies have shown that using semaglutide (the active ingredient in Ozempic) or tirzepatide (the active ingredient in Mounjaro) may increase the risk of thyroid cancer. However, animal ...

In this retrospective study of patients with comorbid type 2 diabetes mellitus and tobacco use disorder (TUD), semaglutide ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... for conditions ranging from heart disease to cancer to neurodegenerative diseases.

Doctors say new research has found a link between weight-loss drugs and cancer, putting users at 'significantly higher risk' ...

For instance, cancer researchers in India conducted a systematic review and meta-analysis of semaglutide and cancer ... including pancreatic and thyroid cancers. In another systematic review ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient ... If you have conditions like kidney disease or a history of thyroid cancer, GLP-1 agonists may not be suitable ...